Erste Asset Management GmbH Has $65.44 Million Stake in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Erste Asset Management GmbH has increased its stake in Agios Pharmaceuticals by 10.9%, now holding approximately 3.85% of the company, valued at $65,439,000.
• Insider James William Burns sold 2,799 shares of Agios Pharmaceuticals, representing an 8.90% decrease in ownership.
• Agios Pharmaceuticals reported a quarterly loss of ($1.93) EPS, missing estimates by ($0.19), although revenue exceeded expectations.

Erste Asset Management GmbH increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 10.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,229,900 shares of the biopharmaceutical company's stock after buying an additional 220,000 shares during the period. Erste Asset Management GmbH owned 3.85% of Agios Pharmaceuticals worth $65,439,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of AGIO. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals during the 4th quarter worth $39,000. CWM LLC increased its stake in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares during the period. Sterling Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares during the period. Finally, Summit Investment Advisors Inc. grew its holdings in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after buying an additional 394 shares during the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 11,085 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $36.67, for a total transaction of $406,486.95. Following the transaction, the chief executive officer directly owned 123,528 shares in the company, valued at approximately $4,529,771.76. This represents a 8.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the sale, the insider directly owned 26,122 shares in the company, valued at $876,131.88. This trade represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,448 shares of company stock worth $2,026,141 over the last 90 days. Company insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Trading Down 1.9%

AGIO stock traded down $0.74 during trading on Monday, hitting $38.06. 101,966 shares of the stock traded hands, compared to its average volume of 703,135. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of 3.46 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The company has a 50 day simple moving average of $36.82 and a 200 day simple moving average of $32.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. As a group, analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on AGIO. Bank of America cut their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Finally, Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.